Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods.
about
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trialsVirtual Raters for Reproducible and Objective Assessments in RadiologyA novel method for volumetric MRI response assessment of enhancing brain tumorsA novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastomaResponse assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patientsResponse criteria for glioma.The role of advanced MR imaging in understanding brain tumour pathology.Discerning tumor status from unstructured MRI reports--completeness of information in existing reports and utility of automated natural language processing.Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.Analysis of heterogeneity in T2-weighted MR images can differentiate pseudoprogression from progression in glioblastoma.Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.Conventional MRI evaluation of gliomas.Multicentre imaging measurements for oncology and in the brain.Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).Longitudinal MRI evidence for decreased survival among periventricular glioblastoma.Evaluation of early imaging response criteria in glioblastoma multiforme.Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgeryProgressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry.Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Activity in Human Glioma Samples Predicts Tumor Presence and Clinical Prognosis.Clinical Evaluation of a Fully-automatic Segmentation Method for Longitudinal Brain Tumor Volumetry.From patient-specific mathematical neuro-oncology to precision medicineBevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyBrain tumor imaging in clinical trials.Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach.Clinical trial end points for high-grade glioma: the evolving landscape.Malignant glioma drug discovery - targeting protein kinases.Volumetric response evaluation after intensity modulated radiotherapy in patients with supratentorial gliomas.Assessment of Brain Tumor Response: RANO and Its Offspring.Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.Intraobserver and interobserver agreement in volumetric assessment of glioblastoma multiforme resection.Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps.Genome-wide copy number analysis in pediatric glioblastoma multiforme.Emerging techniques and technologies in brain tumor imagingSemi-automatic segmentation software for quantitative clinical brain glioblastoma evaluation.Computed Tomography and Magnetic Resonance Imaging Are Equivalent in Mensuration and Similarly Inaccurate in Grade and Type Predictability of Canine Intracranial Gliomas.Analysis of parametric histogram from dynamic contrast-enhanced MRI: application in evaluating brain tumor response to radiotherapy.Response Assessment in Neuro-Oncology Clinical Trials.
P2860
Q26801351-9A8B2470-095E-436F-89F5-00B468A5D186Q27318743-E499B30E-9D42-4677-A02D-BB5062E9DF02Q28743259-31FFFBE3-771D-43D4-ADD7-D4072286A93CQ30408669-013D325E-B5F1-4E72-86D5-C470EA060630Q30607148-D6239ED4-84B4-429E-A167-2905B62744C0Q30692995-69CE535E-91E1-4FEA-852E-A7B39C1CD3C5Q31172444-DA49D872-9381-47DE-AC54-1A1408A21C0FQ33309683-FEF6ADFD-2D4E-49F5-B2FD-0932BA158823Q33457236-4CE57B9C-4A52-468E-B559-824E80F22FACQ33586021-07EEFB92-33A5-431C-8E62-736066653F15Q33698886-E2E2D1B1-BA45-4207-9758-1139179BF571Q33905155-7E1E04A2-C841-4414-8AFF-2105A83FF3D2Q34203916-D95198AB-25F6-4744-AD75-F110ED5B9214Q34203974-879C0B74-9FFA-4870-8888-5C7B1F3D9EBCQ34331320-F226CCFC-64E1-4889-AF90-E2997A8494F7Q35151274-0370CDD2-98EF-4CF4-8062-E4C259A1274AQ35289895-53CD6B13-BF63-43A4-98BE-60A25A6F5158Q35914535-D34732F7-2637-484C-B04E-DBB23AAD1097Q35914767-66D4F1BF-06EB-4CD0-A0B8-7E6471756D7DQ36292996-114FBF65-395A-4862-8826-E9428436FEB5Q36339657-264E9CAB-453A-42A1-9604-BF9BC5BDB326Q36713514-D791DC21-4D8F-46A9-8409-A00C813E361CQ36733380-5132C594-5931-48C7-B585-4CC63617FE5BQ36787777-7E62312B-F34B-4193-9209-E1AAAEF2C867Q36943907-B908DBEB-3E34-4685-8A67-3FA6009FB449Q37083986-BD2C1AE6-38ED-4FA6-A2DD-BF013382021EQ37206334-EA878652-8E54-4528-B108-8A5515A10CB7Q37839482-1853BD4A-9CE7-4788-93D4-E54C7C67435DQ38089834-737FF766-D237-4BB6-967D-ED272FEC65A5Q38467345-144B6190-206B-4CF8-92D7-F7EC5FE2386FQ38855020-F56F1532-DC1B-4B88-9D8B-AA160B08334CQ38958800-15108C98-D38D-4FED-AF95-44A416D97CEEQ39833903-1CDFD41A-94B8-44BC-B3B0-1E11FF107AB8Q40595545-465C2F57-B342-44DF-80AE-93B1BDF0A39FQ40950711-8CC4A2DE-A25E-4586-AB5A-8C4CD7213CB4Q41995781-ACF37850-EE6F-4756-A684-DD2CC7D70F40Q42076427-B402C726-F339-4336-A96E-DA3F7BC3CEE7Q42367945-42E5BB1C-4D8A-4CD3-9AE0-A33F97D840E0Q45840193-30DDC486-4E6C-44E6-9E45-6D15EDDD9301Q45945655-0D3B30B5-1B4A-45C4-9F37-EB333E48DFBC
P2860
Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Validation of neuroradiologic ...... assisted tumor volume methods.
@ast
Validation of neuroradiologic ...... assisted tumor volume methods.
@en
type
label
Validation of neuroradiologic ...... assisted tumor volume methods.
@ast
Validation of neuroradiologic ...... assisted tumor volume methods.
@en
prefLabel
Validation of neuroradiologic ...... assisted tumor volume methods.
@ast
Validation of neuroradiologic ...... assisted tumor volume methods.
@en
P2093
P2860
P1433
P1476
Validation of neuroradiologic ...... assisted tumor volume methods.
@en
P2093
Jan C Buckner
Karla V Ballman
Matthew J Maurer
Rene Sykora
René Castillo
P2860
P304
P356
10.1215/15228517-2005-005
P577
2006-03-02T00:00:00Z